Vivani Medical has raised $15,700,000 in a recent funding round, securing significant investment capital to advance its pre-clinical development. This funding injection underscores investor confidence in the company's innovative approach to chronic disease management.
Vivani Medical operates as a pre-clinical-stage developer focused on long-term pharmaceutical implants. Its mission is to revolutionize the treatment of patients with chronic diseases by addressing medication non-adherence. Leveraging its proprietary NanoPortal™ platform, Vivani creates tiny, sub-dermal drug implants designed to deliver steady levels of medication over target durations of six months or longer. The company's pipeline includes two miniature, long-term GLP-1 implants, NPM-115 (exenatide) and NPM-139 (semaglutide), both targeting obesity and chronic weight management. Additionally, Vivani is developing NPM-119, a lower dose exenatide implant specifically for the treatment of type 2 diabetes.
The $15,700,000 secured will be instrumental in accelerating Vivani's research and development efforts. The company plans to use the funds for continued preclinical studies, expanding its platform capabilities, and preparing for the transition into clinical trials for its lead programs. This capital infusion is crucial for advancing its portfolio of long-acting implants, particularly its GLP-1 candidates, through key developmental milestones.
This investment positions Vivani Medical to further its objective of transforming chronic disease treatment through enhanced patient adherence and sustained drug delivery. The company aims to address substantial unmet medical needs by bringing its novel implantable solutions closer to realization, ultimately impacting patient outcomes.
